Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial.
Fiche publication
Date publication
février 2016
Journal
Lancet (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr COUILLAULT Gérard
Tous les auteurs :
Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, Fischbach M, Magnusson B, Sterba G, Avcin T, Brochard K, Corona F, Dressler F, Gerloni V, Apaz MT, Bracaglia C, Cespedes-Cruz A, Cimaz R, Couillault G, Joos R, Quartier P, Russo R, Tardieu M, Wulffraat N, Bica B, Dolezalova P, Ferriani V, Flato B, Bernard-Medina AG, Herlin T, Trachana M, Meini A, Allain-Launay E, Pilkington C, Vargova V, Wouters C, Angioloni S, Martini A,
Lien Pubmed
Résumé
Most data for treatment of dermatomyositis and juvenile dermatomyositis are from anecdotal, non-randomised case series. We aimed to compare, in a randomised trial, the efficacy and safety of prednisone alone with that of prednisone plus either methotrexate or ciclosporin in children with new-onset juvenile dermatomyositis.
Mots clés
Adolescent, Analysis of Variance, Anti-Inflammatory Agents, administration & dosage, Child, Child, Preschool, Cyclosporine, administration & dosage, Dermatologic Agents, administration & dosage, Dermatomyositis, drug therapy, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Kaplan-Meier Estimate, Male, Methotrexate, administration & dosage, Prednisone, administration & dosage, Treatment Outcome
Référence
Lancet. 2016 Feb;387(10019):671-8